Kai-Jye Lou

Education

M.S., biomedical engineering, and B.S., computational and systems biology, University of California, Los Angeles

Summary of Experience

Mr. Lou specializes in the planning and execution of evidence generation and market access strategy for pharmaceutical, diagnostic, and medical device products. His focus areas include literature reviews, landscape analyses, formulary dossiers, value evidence communication tools, and research manuscripts. Mr. Lou’s expertise includes hematologic malignancies, solid tumors, cardiovascular diseases, hematology, neurodegenerative diseases, rare diseases, and therapeutic platforms. He has supported new product launches as well as label expansions with formulary dossiers and associated disease education materials, payer value propositions, and payer objection handlers in both pre-approval and post-approval settings. He has also supported evidence submission packages for Medicare coverage determinations and Institute for Clinical and Economic Review (ICER) reviews; literature reviews to inform evidence strategy and health technology assessments (HTAs); and the development of technical reports, conference abstracts, and research manuscripts. Prior to joining Analysis Group, Mr. Lou spent a decade in the biotech sector tracking emerging biomedical technologies, competitive landscapes, and industry trends. He has authored more than 200 articles assessing the scientific and commercial prospects of early-stage biomedical technologies with input from thought leaders in academia and industry.